Other highlights from NeurogesX’s 4Q include a 54 percent increase in hospital purchases of its Qutenza (capsaicin) 8 percent patch. Qutenza is a localized dermal delivery system containing prescription-strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia.
The company’s most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.
Read the news release about NeurogesX’s 4Q financial results.
Related Articles on Pain Management:
6 Statistics About Orthopedic and Pain Management Revenue Per Case
70 of the Best Pain Management Physicians in America
4 Points on Medication Management for Back Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.